Document is current
Any future updates will be listed below
-
Authors
Mori, Shunta
Izumi, Hiroki
Araki, Mitsugu https://orcid.org/0000-0002-7810-4905
Liu, Jie
Tanaka, Yu
Kagawa, Yosuke
Sagae, Yukari
Ma, Biao https://orcid.org/0000-0003-0410-4408
Isaka, Yuta https://orcid.org/0000-0002-3974-0650
Sasakura, Yoko
Kumagai, Shogo
Sakae, Yuta
Tanaka, Kosuke
Shibata, Yuji
Udagawa, Hibiki
Matsumoto, Shingo
Yoh, Kiyotaka
Okuno, Yasushi https://orcid.org/0000-0003-3596-4208
Goto, Koichi https://orcid.org/0000-0002-3023-2510
Kobayashi, Susumu S. https://orcid.org/0000-0003-2262-4001
-
Funding
Funding for this research was provided by:
Princess Takamatsu Cancer Research Fund (18-250)
MEXT | Japan Society for the Promotion of Science (16K21746, 22H03084, 120207408, JP20K17215, JP21K06510)
- License Information
-
More Information
Article History
Received: 8 June 2023
Accepted: 27 March 2024
First Online: 4 April 2024
Competing interests
: The authors declare the following competing interests. S.Mo. reports no conflicts of interest in this study. Y.T. reports personal fees (honoraria) from Chugai, Eli Lilly, AstraZeneca, Taiho. H.I. reports research support from Amgen, Ono, Takeda, Eisai and personal fees (honoraria) from Ono, Chugai, AstraZeneca, Merck. Y.S. reports research support from Ono, MSD, and personal fees (honoraria) from Ono, Chugai, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Pfizer. H.U. reports research support from Takeda, Boehringer Ingelheim, Taiho and personal fees (honoraria) from Taiho. S.Ma. reports research support from Chugai, Novartis, Eli Lilly, Merck, MSD, and personal fees (honoraria) from AstraZeneca, Chugai, Novartis, Pfizer and Eli Lilly. K.Y. reports research support from AstraZeneca, Eli Lilly, Phizer, Diichi sankyo, Abbvie, Taiho, MSD, Takeda, Chugai, and personal fees (honoraria) from Chugai, AstraZeneca, Bristol-Myers Squibb, Daiichi sankyo, Janssen, Eli Lilly, Taiho, Novaritis, Kyowa kirin, Boehringer Ingelheim. G.K. reports research support from Amgen, Amgen Astellas BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim Japan, Bristol-Myers Squibb, Blueprint Medicines, Chugai, Daiichi sankyo, Eisai, Eli Lilly, Haihe Biopharma, Ignyta, Janssen, KISSEI, Kyowa Kirin, Life Technologies, Loxo Oncology., Medical & Biological Laboratories, Merck, Merus, MSD, NEC Corporation, Novartis, Ono, Pfizer, Sumitomo Dainippon, Spectrum Pharmaceuticals, Sysmex Corporation, Taiho, Takeda, Turning Point Therapeutics, and personal fees (honoraria) from Amgen, Amoy Diagnosties, Amgen Astellas BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Daiichi sankyo, Eisai, Eli Lilly Japan, Guardant Health, Janssen, Thermo Fisher Scientifi, Medpace, Merck, MSD, Novartis Pharma, Ono, Otsuka, Taiho, and Takeda. SSK reports grants from Boehringer Ingelheim, MiRXES, Johnson&Johnson, and Taiho Therapeutics, as well as personal fees from AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Chugai Pharmaceutical, and Takeda Pharmaceuticals plus royalties from Life Technologies. Other authors declare no conflicts of interest.
